Recombinant Human TNFRSF18 Protein (Gln26-Pro162), C-mFc and 6×His-tagged

• Cat.No.: TNFRSF18-601H
• Product Overview: Recombinant Human TNFRSF18 Protein (Gln26-Pro162) with C-mFc and 6×His tag was expressed in HEK293.

Specification

• Description: This gene encodes a member of the TNF-receptor superfamily. The encoded receptor has been shown to have increased expression upon T-cell activation, and it is thought to play a key role in dominant immunological self-tolerance maintained by CD25(+)CD4(+) regulatory T cells. Knockout studies in mice also suggest the role of this receptor is in the regulation of CD3-driven T-cell activation and programmed cell death. Three alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
• Source: HEK293
• Species: Human
• Tag: His&mFc
• Form: Lyophilized
• Molecular Mass: 50-52 kDa
• Protein length: Gln26-Pro162
• Purity: > 95% as determined by SDS-PAGE and Coomassie blue staining.
• Storage: Store at -80 centigrade for 12 months (Avoid repeated freezing and thawing)
• Storage Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 26 % trehalose is added as protectants before lyophilization.

Gene Information

• Gene Name: TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens (human) ]
• Official Symbol: TNFRSF18
• Synonyms: TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D
• Gene ID: 8784
• mRNA Refseq: NM_004195
• Protein Refseq: NP_004186
• MIM: 603905
• UniProt ID: Q9Y5U5

Reviews

12/20/2021

This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

03/05/2020

Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

10/01/2017

The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

Q&As

What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment?

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment?

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies?

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes?

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies?

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.